Title:
CAR-T CELL AND USE THEREOF IN TREATMENT OF NON-SMALL CELL LUNG CANCER
Document Type and Number:
WIPO Patent Application WO/2024/040681
Kind Code:
A1
Abstract:
The present invention relates to an uPAR-targeted third-generation chimeric antigen receptor, immune effector cells (e.g., T cells, NK cells) engineered to express the chimeric antigen receptor of the present invention, and a use of the engineered immune effector cells in the treatment of uPAR-positive non-small cell lung cancer (NSCLC).
Inventors:
ZHONG XIAO SONG (CN)
TONG SHUAI (CN)
TONG SHUAI (CN)
Application Number:
PCT/CN2022/122202
Publication Date:
February 29, 2024
Filing Date:
September 28, 2022
Export Citation:
Assignee:
CARRIAGE PHARMACEUTIC BEIJING CO LTD (CN)
International Classes:
C07K19/00; A61K35/17; A61P35/00; C12N5/10; C12N15/62; C12N15/63
Domestic Patent References:
| WO2020160518A1 | 2020-08-06 |
Foreign References:
| CN114671957A | 2022-06-28 | |||
| CN105368859A | 2016-03-02 | |||
| CN114920841A | 2022-08-19 | |||
| CN101466737A | 2009-06-24 |
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: